Fertility warning
This medicine may affect fertility.
Leaflet DECITABINA ACCORD 50mg powder for concentrate for solution for infusion
- Product code:
- W71846001
- Quantity:
- 1
- Indicated for:
- hematologic malignancies
- Route of administration:
- infusion
- Substance:
- decitabine (antimetabolite antineoplastic)
- ATC
- L01BC08 — Antineoplastic and immunomodulating agents | Antimetabolites | Pyrimidine analogues
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Decitabine is a hypomethylating agent used for the treatment of myelodysplastic syndromes and acute myeloid leukemia. It works by inhibiting DNA methyltransferase, leading to the reactivation of tumor suppressor genes and inhibition of cancer cell growth.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's condition and response to therapy. Common side effects include nausea, anemia, neutropenia, and thrombocytopenia.
Decitabine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe hematological complications.
This medication is an important option for patients with malignant hematological disorders, helping to improve their prognosis.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's condition and response to therapy. Common side effects include nausea, anemia, neutropenia, and thrombocytopenia.
Decitabine is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe hematological complications.
This medication is an important option for patients with malignant hematological disorders, helping to improve their prognosis.
General data about DECITABINA ACCORD 50mg
- Substance:
- decitabine
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W71846001
- Concentration:
- 50mg
- Pharmaceutical form:
- powder for concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for decitabine
- 40mg
- 50mg